16 March 2024 CEMAG Care and Concept Foundation visited ACME’s facilities in Dhaka, Bangladesh where the signing ceremony took place. Together they started a collaboration to ensure an increasing access to quality assured abortion medication for women.
CEMAG Care, ACME Laboratories Ltd., and Concept Foundation join forces for women's health with a shared goal: facilitating the access to safe and effective quality-assured induced abortion products for all women
CEMAG Care announces its partnership with ACME Laboratories Ltd, a pharmaceutical manufacturer based in Bangladesh and founded in 1954 and with Concept Foundation, an international non-profit organisation based in Geneva, Switzerland. This joint initiative aims to develop abortifacient pills. As a laboratory committed to women’s health, abortion has always been a part of CEMAG Care activities. Through this partnership CEMAG Care reasserts its willingness to serve women’s health.
The collaboration defines that CEMAG Care having substantial experience and expertise, will provide up-front investment & technical support to ACME for development of the product and generation of safety and efficacy data. Concept Foundation will arrange, support, and coordinate the partnership and ACME having requisite facilities & expertise will develop and manufacture the product. The commercialisation will be shared between ACME and CEMAG Care.
“This partnership is the practical result of years of research and battles to improve health for women. Beyond France, Cemag Care plans to make this product available in as many countries as possible. This breakthrough marks a decisive new stage for CEMAG Care, » said André Ulmann who made the “morning-after pill”, available to all French women without prescription since 1999.